Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00071643 · ClinicalTrials.gov registry record · NA

Preventing Post-Stroke Depression

A NA study of Depression and Cerebrovascular Accident, sponsored by Robert G. Robinson.

Completed
Registry status
NA
Development phase
201
Enrollment target
3
Study locations

NCT00071643: Completed NA study of Depression and Cerebrovascular Accident, sponsored by Robert G. Robinson.

NCT00071643 is a NA study of Depression and Cerebrovascular Accident that has completed, run by Robert G. Robinson. The registered enrollment target is 201 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00071643, a NA study of Depression and Cerebrovascular Accident, has completed, sponsored by Robert G. Robinson.

COMPLETED
Registry status
NA
Development phase
201 participants
Enrollment target
3
Study locations

Study Summary

This study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.

Interventions

  • OTHER Placebo
  • DRUG Escitalopram
  • BEHAVIORAL Problem Solving Therapy

Study Locations (3)

Illinois

  • University of Chicago - Chicago

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

New York

  • Burke Rehabilitation Hospital - White Plains

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2002-09
Est. Completion 2008-11
Phase NA
Robert G. Robinson

1 total trials

What the finished NCT00071643 record still lists

NCT00071643 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (74% lower).

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00071643 reports a single indexed study location in Illinois, Iowa, New York.

Frequently Asked Questions

What is clinical trial NCT00071643 about?

NCT00071643 is a clinical study titled "Preventing Post-Stroke Depression". This study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.

What is the current status of trial NCT00071643?

This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2002-09. Estimated completion is 2008-11.

What conditions does trial NCT00071643 study?

This clinical trial studies the following conditions: Depression, Cerebrovascular Accident.

What interventions are being tested in trial NCT00071643?

The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG), Problem Solving Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00071643?

This trial is sponsored by Robert G. Robinson, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00071643 being conducted?

This trial has 3 study locations across Illinois, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00071643's enrollment target sits among peer trials

201 208th of 679 higher than 472 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00071643, the US trial registry maintained by the National Library of Medicine. NCT00071643 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.